Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:43 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia
NCT02538614 · Gilead Sciences · PHASE1 · terminated · last registry update 2020-11-25 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Gilead Sciences |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PIK3CD within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-11-09Also stopped (withdrawn): Virginia Commonwealth University, Dose combination 1-1 + dose combination 1-2 (NCT03639324)
- 2021-11-04Also stopped (terminated): OHSU Knight Cancer Institute, Dasatinib + Idelalisib (NCT01620216)
- 2021-10-11Phase 3 first posted: Incyte Corporation, parsaclisinib + placebo (NCT05073458)
- 2021-10-11Also stopped (terminated): Prince of Songkla University, BKM120 (NCT01806649)
- 2021-10-07Results posted on the registry: Pfizer, PF-05212384 (gedatolisib) + Docetaxel (NCT01920061)
- 2021-10-04Results posted on the registry: OHSU Knight Cancer Institute, Dasatinib + Idelalisib (NCT01620216)
- 2021-09-05Also stopped (terminated): PETHEMA Foundation, Idelalisib (NCT03742323)
- 2021-07-16Results posted on the registry: Columbia University, Carfilzomib + TGR-1202 (NCT02867618)
- 2021-07-16Also stopped (terminated): Columbia University, Carfilzomib + TGR-1202 (NCT02867618)
- 2021-07-16Results posted on the registry: Columbia University, TGR-1202 (NCT03178201)
- 2021-07-16Also stopped (terminated): Columbia University, TGR-1202 (NCT03178201)
- 2021-06-23Results posted on the registry: Restorbio Inc., Dactolisib (NCT04668352)
- 2021-06-21Results posted on the registry: Memorial Sloan Kettering Cancer Center, Buparlisib (NCT01551030)
- 2021-06-11Also stopped (terminated): Duke University, REMD-477 (NCT04253223)
- 2021-05-20Also stopped (terminated): Aptevo Therapeutics, 20 mg/kg TRU-016 + Rituximab + 10 mg/kg TRU-016 + Rituximab (NCT01644253)
- 2021-04-19Phase 3 first posted: Incyte Corporation, parsaclisib + rituximab (NCT04849715)
- 2021-04-02Also stopped (terminated): Gilead Sciences, Idelalisib + Nab-paclitaxel (NCT02468557)
- 2021-04-01Results posted on the registry: Bayer, Copanlisib (ALIQOPA, BAY80-6946) (NCT03172884)
- 2021-03-29Also stopped (terminated): UNICANCER, Copanlisib + Cetuximab (NCT02822482)
- 2021-03-24Results posted on the registry: Incyte Corporation, Parsaclisib (NCT03627065)
- 2021-03-22Results posted on the registry: Gilead Sciences, Idelalisib + Nab-paclitaxel (NCT02468557)
- 2021-03-19Results posted on the registry: Gilead Sciences, Idelalisib (NCT02242045)
- 2021-03-18Results posted on the registry: Gilead Sciences, Idelalisib + Rituximab (NCT01088048)
- 2021-03-15Phase 3 first posted: Incyte Corporation, parsaclisib + rituximab (NCT04796922)
- 2021-02-10Also stopped (terminated): Restorbio Inc., RTB101 + Placebo (NCT04409327)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision